» Articles » PMID: 21895520

Identification of Plasma Biomarkers of TBI Outcome Using Proteomic Approaches in an APOE Mouse Model

Overview
Journal J Neurotrauma
Publisher Mary Ann Liebert
Date 2011 Sep 8
PMID 21895520
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The current lack of diagnostic and prognostic biomarkers for traumatic brain injury (TBI) confounds treatment and management of patients and is of increasing concern as the TBI population grows. We have generated plasma proteomic profiles from mice receiving TBI by controlled cortical impact at either 1.3 mm or 1.8 mm depth, comparing these against those of sham injured-animals to identify plasma biomarkers specific to mild or severe TBI at 24 hours, 1 month, or 3 months post-injury. To identify possible prognostic biomarkers, we used apolipoprotein E (APOE)3 and APOE4 transgenic mice, which demonstrate relatively favorable and unfavorable outcomes respectively, following TBI. Using a quantitative proteomics approach (isobaric tagging for relative and absolute quantitation--iTRAQ) we have identified proteins that are significantly modulated as a function of TBI and also in response to the TBI*APOE genotype interaction, the latter representing potential prognostic biomarkers. These preliminary data clearly demonstrate plasma protein changes that are not only injury dependent but also interaction dependent. Importantly, these results demonstrate the presence of TBI-dependent and interaction-dependent plasma proteins at a 3-month time point, which is a considerable time post-injury in the mouse model, and will potentially be of significance for combat veterans receiving assessment at extended periods post-injury. Furthermore, our identification of clusters of functionally related proteins indicates disturbance of particular biological modules, which potentially increases their value beyond that of solitary biomarkers.

Citing Articles

Unbiased Proteomic Approach Identifies Pathobiological Profiles in the Brains of Preclinical Models of Repetitive Mild Traumatic Brain Injury, Tauopathy, and Amyloidosis.

Ojo J, Crynen G, Algamal M, Vallabhaneni P, Leary P, Mouzon B ASN Neuro. 2020; 12:1759091420914768.

PMID: 32241177 PMC: 7132820. DOI: 10.1177/1759091420914768.


Dynamics of clusterin protein expression in the brain and plasma following experimental traumatic brain injury.

Gupta S, Lipponen A, Paldanius K, Puhakka N, Pitkanen A Sci Rep. 2019; 9(1):20208.

PMID: 31882899 PMC: 6934775. DOI: 10.1038/s41598-019-56683-6.


Unbiased Proteomic Approach Identifies Unique and Coincidental Plasma Biomarkers in Repetitive mTBI and AD Pathogenesis.

Ojo J, Crynen G, Reed J, Ajoy R, Vallabhaneni P, Algamal M Front Aging Neurosci. 2019; 10:405.

PMID: 30618712 PMC: 6305374. DOI: 10.3389/fnagi.2018.00405.


Current and Emerging Technologies for Probing Molecular Signatures of Traumatic Brain Injury.

Ercole A, Magnoni S, Vegliante G, Pastorelli R, Surmacki J, Bohndiek S Front Neurol. 2017; 8:450.

PMID: 28912750 PMC: 5582086. DOI: 10.3389/fneur.2017.00450.


Serum Proteome Alterations in Patients with Cognitive Impairment after Traumatic Brain Injury Revealed by iTRAQ-Based Quantitative Proteomics.

Xiong X, Liang Q, Zhang C, Wang Y, Huang W, Peng W Biomed Res Int. 2017; 2017:8572509.

PMID: 28251161 PMC: 5303854. DOI: 10.1155/2017/8572509.